Table 3.

Clinical Dementia Rating (CDR) and psychological test scores for apolipoprotein E ε4 allele (APOE4) (+) subjects ^a.

	Startup		Follow-Up		Treatment × Time Interaction b
	Active	Placebo	Active	Placebo	Active	Placebo	p Value
MMSE	27.1 ± 2.4	26.7 ± 2.3	26.9 ± 2.3	25.1 ± 3.6	−0.25 ± 1.4	−1.6 ± 1.5	0.0253
gloCDR	0.5	0.5	0.25 ± 0.27	0.50 ± 0.21	−0.25 ± 0.27	0 ± 0.21	0.0261
CDRsob	0.69 ± 0.37	1.25 ± 0.50	0.75 ± 0.65	1.33 ± 0.86	0.06 ± 0.68	0.08 ± 0.82	0.406
WMS-1	9.3 ± 3.4	6.5 ± 4.9	8.4 ± 3.1	6.8 ± 5.2	−0.88 ± 2.9	0.25 ± 2.5	0.592
WMS-2	5.8 ± 3.7	4.9 ± 4.5	6.4 ± 4.4	4.6 ± 5.5	0.63 ± 3.2	−0.33 ± 2.4	0.670
ADAS	10.9 ± 5.8	17.6 ± 8.9	12.2 ± 9.4	17.5 ± 9.9	1.3 ± 6.4	−0.13 ± 5.3	0.207
GDS	1.6 ± 1.1	2.1 ± 1.4	1.4 ± 2.0	2.6 ± 2.2	−0.25 ± 2.7	0.5 ± 1.9	0.165
GDS	2.5 ± 1.9	2.5 ± 2.4	2.6 ± 2.9	2.6 ± 2.1	0.1 ± 2.7	0.1 ± 2.0	0.943

^a We performed the same statistical analysis, described in Table 2. ^b The change between start-up and follow-up.